Less Ads, More Data, More Tools Register for FREE

Pin to quick picksDCC Regulatory News (DCC)

Share Price Information for DCC (DCC)

Share Price is delayed by 15 minutes
Get Live Data
6,015.00    -10.00 (-0.17%)
Bid:
6,010.00
Ask:
6,020.00
Spread: 10.00 (0.166%)
Market Cap: £5.14b
DCC Live PriceLast checked at - London Stock Exchange

Intraday DCC Share Chart

Form 38.5b- DCC PLC

1 Jun 2026 13:25

RNS Number : 5041G
Goldman Sachs & Co. LLC
01 June 2026
 

 

FORM 38.5(b)

 

IRISH TAKEOVER PANEL

 

DISCLOSURE UNDER RULE 38.5(b) OF THE IRISH TAKEOVER PANEL ACT, 1997, TAKEOVER RULES, 2013

 

DEALINGS BY CONNECTED EXEMPT PRINCIPAL TRADERS WITHOUT RECOGNISED INTERMEDIARY STATUS, OR WITH RECOGNISED INTERMEDIARY STATUS BUT NOT DEALING IN A CLIENT-SERVING CAPACITY

 

1. KEY INFORMATION

 

Name of exempt principal trader

GOLDMAN SACHS & CO. LLC

Company dealt in

DCC PLC

Class of relevant security to which the dealings being disclosed relate (Note1)

EUR 0.25 ordinary shares

Date of dealing

29 May 2026

 

2. INTERESTS AND SHORT POSITIONS

 

(a) Interests and short positions (following dealing) in the class of relevant security dealt in  (Note 2)

 

Long

Short

Number

(%)

Number

(%)

(1) Relevant securities

74,783

(0.09)

74,775

(0.09)

(2) Derivatives (other than options)

0

(0.00)

189

(0.00)

(3) Options and agreements to purchase/sell

0

(0.00)

0

(0.00)

Total

74,783

(0.09)

74,964

(0.09)

 

(b) Interests and short positions in relevant securities of the company, other than the class dealt in  (Note 2)

 

Class of relevant security:

Long

Short

Number

(%)

Number

(%)

(1) Relevant securities

(2) Derivatives (other than options)

(3) Options and agreements to purchase/sell

Total

 

3. DEALINGS (Note 3)

(a) Purchases and sales

 

Purchase/sale

Number of relevant securities

Price per unit  (Note 4)

Sale (Loan New)

2

N/A

 

(b) Derivatives transactions (other than options transactions)

 

Product name, e.g. CFD

Nature of transaction  (Note 5)

Number of relevant securities  (Note 6)

Price per unit  (Note 4)

 

(c) Options transactions in respect of existing relevant securities

 

(i) Writing, selling, purchasing or varying

 

Product name,e.g. call option

Writing, selling, purchasing, varying etc.

Number of securities to which the option relates  (Note 7)

Exercise price

Type, e.g. American, European etc.

Expiry date

Option money paid/received per unit  (Note 4)

 

(ii) Exercising

 

Product name,e.g. call option

Number of securities

Exercise price per unit  (Note 4)

 

(d) Other dealings (including transactions in respect of new securities)  (Note 3)

 

Nature of transaction  (Note 7)

Details

Price per unit (if applicable)  (Note 4)

 

4. OTHER INFORMATION

 

Agreements, arrangements or understandings relating to options or derivatives

 

Full details of any agreement, arrangement or understanding between the person disclosing and any other person relating to the voting rights of any relevant securities under any option referred to on this form or relating to the voting rights or future acquisition or disposal of any relevant securities to which any derivative referred to on this form is referenced. If none, this should be stated. 

NONE

 

Is a Supplemental Form 8 attached? (Note 9) NO

 

Date of disclosure

01 June 2026

Contact name

Papa Lette and Andrzej Szyszka

Telephone number

+33(1) 4212 1459 / +48(22) 317 4817

Name of offeree/offeror with which connected

ENERGY CAPITAL PARTNERS, LLC AND KOHLBERG KRAVIS ROBERTS & CO. L. P. (TOGETHER THE "CONSORTIUM")

Nature of connection (Note 9)

Advisor to Offeree

 

 

This information is provided by RNS, the news service of the London Stock Exchange. RNS is approved by the Financial Conduct Authority to act as a Primary Information Provider in the United Kingdom. Terms and conditions relating to the use and distribution of this information may apply. For further information, please contact rns@lseg.com or visit www.rns.com.RNS may use your IP address to confirm compliance with the terms and conditions, to analyse how you engage with the information contained in this communication, and to share such analysis on an anonymised basis with others as part of our commercial services. For further information about how RNS and the London Stock Exchange use the personal data you provide us, please see our Privacy Policy.
 
END
 
 
ITPUPUCPQUPQGPG
Date   Source Headline
8th Jul 202011:38 amRNSHolding in Company TR-1
24th Jun 20209:39 amRNSHolding in Company TR-1
18th Jun 202012:25 pmRNS2020 Annual Report, Notice of AGM and Proxy Form
3rd Jun 202010:10 amRNSHolding in Company TR-1
29th May 202011:27 amRNSTotal Voting Rights
28th May 20206:21 pmRNSDirector/PDMR Shareholding
28th May 20201:02 pmRNSHolding in Company TR-1
19th May 20205:04 pmRNSBoard Changes
19th May 20207:00 amRNSResults for the year ended 31 March 2020
14th May 20203:30 pmRNSHolding in Company TR-1
27th Apr 20206:02 pmRNSDisclosure of Rights Attached to Equity Shares
16th Apr 20204:24 pmRNSDirector Declaration
9th Apr 20204:21 pmRNSHolding in Company TR-1
3rd Apr 20204:01 pmRNSHolding in Company TR-1
25th Mar 20203:22 pmRNSHolding in Company TR-1
25th Mar 20207:00 amRNSDCC Healthcare announces acquisition of Amerilab
19th Mar 20204:10 pmRNSHolding in Company TR-1
19th Mar 20209:46 amRNSHolding in Company TR-1
18th Mar 202012:14 pmRNSHolding in Company TR-1
6th Mar 20204:08 pmRNSHolding in Company TR-1
28th Feb 202010:54 amRNSTotal Voting Rights
24th Feb 20208:38 amRNSBoard Change
24th Feb 20208:34 amRNSChief Financial Officer Succession
12th Feb 20209:10 amRNSHolding in Company TR-1
4th Feb 20207:00 amRNSInterim Management Statement
17th Jan 20209:23 amRNSHolding in Company TR-1
3rd Jan 202010:03 amRNSHolding in Company - TR1
23rd Dec 201912:44 pmRNSHolding in Company TR-1
5th Dec 20195:44 pmRNSHolding in Company - TR1
29th Nov 20191:39 pmRNSTotal Voting Rights
27th Nov 20199:18 amRNSDirector Declaration
18th Nov 20196:14 pmRNSDirector/PDMR Shareholding
12th Nov 20197:00 amRNSResults for the six months ended 30 September 2019
12th Nov 20197:00 amRNSDCC Healthcare acquires Ion Laboratories
7th Nov 201911:30 amRNSHolding in Company TR-1
23rd Oct 20192:25 pmRNSHolding in Company TR-1
21st Oct 20195:01 pmRNSHolding in Company TR-1
18th Oct 20194:46 pmRNSHolding in Company TR-1
17th Oct 20199:43 amRNSHolding in Company TR-1
25th Sep 20195:39 pmRNSHolding in Company TR-1
4th Sep 20199:57 amRNSHolding in Company TR-1
9th Aug 201910:42 amRNSHolding in Company TR-1
7th Aug 20199:23 amRNSHolding in Company TR-1
31st Jul 20192:58 pmRNSTotal Voting Rights
16th Jul 20196:14 pmRNSDirector/PDMR Shareholding
12th Jul 20193:06 pmRNSResult of AGM
12th Jul 20197:00 amRNSInterim Management Statement
5th Jul 20199:06 amRNSHolding in Company TR-1
19th Jun 20199:22 amRNSHolding in Company TR-1
13th Jun 201911:37 amRNS2019 Annual Report, Notice of AGM and Proxy Form

Due to London Stock Exchange licensing terms, we stipulate that you must be a private investor. We apologise for the inconvenience.

To access our Live RNS you must confirm you are a private investor by using the button below.